论文部分内容阅读
对于演变期急性心肌梗塞(AMI),应用Alteplase(单链重组人组织型纤溶酶原激活剂,rt-PA)治疗,能使梗塞区供血冠脉迅速恢复通畅,限制梗塞范围,保存左室功能,提高存活率。但本品半减期短,血浆纤维蛋白原消耗较少,易于早期发生再次阻塞,故需继以肝素治疗。 644例AMI。随机分为肝素组(324例)和肝素对照组(320例)。肝素组为症状开始6小时内给予Alteplase 100mg+阿司匹林
For AMI, Alteplase (single-chain recombinant human tissue plasminogen activator, rt-PA) can rapidly and patency the coronary arteries in the infarcted area, limit the extent of infarction and preserve the left ventricular Function, improve survival rate. However, this product half-cut short, less consumption of plasma fibrinogen, easy to early occlusion again, so need to follow the heparin treatment. 644 cases of AMI. Randomly divided into heparin group (324 cases) and heparin control group (320 cases). The heparin group was given Alteplase 100 mg plus aspirin within 6 hours of onset of symptoms